| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/04/2001 | WO2001072837A2 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 10/04/2001 | WO2001072836A2 G-protein coupled receptors |
| 10/04/2001 | WO2001072830A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 10/04/2001 | WO2001072823A1 Crystal structure of the (aml1 runt domain) / (cbfbeta) heterodimer and the ternary complex with dna |
| 10/04/2001 | WO2001072781A2 Human genes and expression products |
| 10/04/2001 | WO2001072780A2 Polynucleotides for diagnosing mammary gland cancer |
| 10/04/2001 | WO2001072779A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 10/04/2001 | WO2001072778A2 Method of identifying inhibitors of tie-2 |
| 10/04/2001 | WO2001072777A2 Human transcription factors |
| 10/04/2001 | WO2001072773A2 Genes isolated from dendritic cells, gene products and methods employing the same |
| 10/04/2001 | WO2001072772A2 Calcium binding regulatory subunit |
| 10/04/2001 | WO2001072721A2 Synergistic methods and compositions for treating cancer |
| 10/04/2001 | WO2001072692A1 Malonamic acids and derivatives thereof as thyroid receptor ligands |
| 10/04/2001 | WO2001072685A2 Polyamine analogues as cytotoxic agents |
| 10/04/2001 | WO2001072347A1 Agents promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin |
| 10/04/2001 | WO2001072341A2 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation |
| 10/04/2001 | WO2001072336A1 Compounds for targeting |
| 10/04/2001 | WO2001072326A1 Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases |
| 10/04/2001 | WO2001072323A2 Use of insulin for the treatment of cartilagenous disorders |
| 10/04/2001 | WO2001072319A1 Tea catechin formulations and processes for making same |
| 10/04/2001 | WO2001072318A1 Tea catechins in sustained release formulations as cancer specific proliferation inhibitors |
| 10/04/2001 | WO2001072311A1 Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death |
| 10/04/2001 | WO2001072304A1 A novel anti-microbial composition and method for producing the same |
| 10/04/2001 | WO2001072302A1 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| 10/04/2001 | WO2001072298A1 Treatments for immune-mediated ear disorders |
| 10/04/2001 | WO2001072296A1 Method of inhibiting the expression of inflammatory cytokines and chemokines |
| 10/04/2001 | WO2001072295A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 10/04/2001 | WO2001072294A2 Method of treating hepatitis delta viral infection |
| 10/04/2001 | WO2001072291A2 Treatment of movement disorders with metabotropic glutamate receptor antagonist |
| 10/04/2001 | WO2001072290A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 10/04/2001 | WO2001072281A2 Microspheres for active embolization |
| 10/04/2001 | WO2001072275A1 Oxidative fluorinator compounds as antimicrobials |
| 10/04/2001 | WO2001072264A2 Pro-liposomal encapsulated preparations (iv) |
| 10/04/2001 | WO2001044198A8 Amphiphilic quinolylpolyamines as transfer agents for biologically active macromolecules |
| 10/04/2001 | WO2001043704A8 A skin care composition that mediates cell to cell communication |
| 10/04/2001 | WO2001032070A3 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 10/04/2001 | WO2001019373A3 Methods and compositions for modulating responsiveness to corticosteroids |
| 10/04/2001 | WO2001019322A3 Use of csaids in rhinovirus infection |
| 10/04/2001 | WO2001016319A3 Compositions and methods for the treatment of immune related diseases |
| 10/04/2001 | WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 10/04/2001 | WO2001013956A3 Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications |
| 10/04/2001 | WO2000053231A3 Fatty acid-anticancer conjugates and uses thereof |
| 10/04/2001 | WO2000047625A9 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 10/04/2001 | WO2000039279A9 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 10/04/2001 | US20010027211 Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents |
| 10/04/2001 | US20010027210 Administering a synergistic mixture of a compound of the xanthenone acetic acid class (5,6-dimethylxanthenone-4-acetic acid) and either paclitaxel or docetaxel; antitumor and -carcinogenic agents |
| 10/04/2001 | US20010027209 Canolide analogues or derivatives of 2-oxo-6,7,8,10,11,12-2H-benzo(1,2-b:3,4-b':5,6-b")tripyran; treating and prevention of mycobacterium infections; tuberculosis; HIV; viricides |
| 10/04/2001 | US20010027201 Non-systemic control of parasites |
| 10/04/2001 | US20010027199 Administering a Tumor Necrosis Factor-alpha inhibitor from the group of metalloproteinase inhibitors, quinolones, corticoids, thalidomide, lazaroides, pentoxyphyllines, hydroxamic and carbocyclic acids; spinal disk hernias |
| 10/04/2001 | US20010027192 A gastrointestinal mucosa-adherent solid comprising an anti-Helicobacter pylori antibiotic and a proton pump inhibitor (antiulcer); synergistic; potentiation; side effect reduction |
| 10/04/2001 | US20010027190 Plant sterols and stanols and a mixture of two or three different emulsifiers of given HLB ranges; for low fat, fat-free, and triglyceride-free foods; good mouthfeel |
| 10/04/2001 | US20010027182 Spinocerebellar ataxia type 1 (SCA1); using chaperone proteins to aid in recognition/hydrolysis of mutant ataxin-1 by the proteasome; treating Alzheimer's, Parkinson's, prion disorders, dentatorubral-pallidoluysian atrophy and SCA1 |
| 10/04/2001 | US20010027181 Treatment or prophylaxis of ischemic heart disease |
| 10/04/2001 | US20010027180 GLP-2 formulations |
| 10/04/2001 | US20010027175 Inhibiting tumor necrosis factor-alpha (TNF-a) for treating nerve conditions such as sciatica by administering antiinflammatory agent etanercept or infliximab |
| 10/04/2001 | US20010026810 Polyurethane prepolymer with polyoxyethylene, polyoxypropylene or propylene glycol; absorbtive, contours to wound site; maintains moisture for healing; may contain fungicidal, bactericidal and deodorizing additives |
| 10/04/2001 | EP1138330A1 Combination of trimebutine with an opioid analgesic |
| 10/04/2001 | EP1138320A2 Floating forms containing drug, polyvinyl acetate and polyvinyl pyrrolidone, their use and preparation |
| 10/04/2001 | EP1138314A2 Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues |
| 10/04/2001 | EP1138313A1 Proliposomes |
| 10/04/2001 | EP1137949A1 Assays for compounds which increase phospholipase a2 activity |
| 10/04/2001 | EP1137948A1 Methods and compositions to lower plasma cholesterol levels |
| 10/04/2001 | EP1137946A1 Use of vascular endothelial growth factor (vegf) |
| 10/04/2001 | EP1137810A2 A$g(b)-PEPTIDE SCREENING ASSAY |
| 10/04/2001 | EP1137806A1 Detection of rantes gene promoter polymorphisms |
| 10/04/2001 | EP1137805A1 Methods of facilitating vascular growth |
| 10/04/2001 | EP1137780A1 Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp |
| 10/04/2001 | EP1137773A2 Growth factor homolog zvegf3 |
| 10/04/2001 | EP1137771A2 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |
| 10/04/2001 | EP1137665A1 Cark protein and nucleic acid molecules and uses therefor |
| 10/04/2001 | EP1137658A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES |
| 10/04/2001 | EP1137438A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors |
| 10/04/2001 | EP1137436A1 Stimulation of t cells against self antigens using ctla-4 blocking agents |
| 10/04/2001 | EP1137427A1 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators |
| 10/04/2001 | EP1137426A1 Cancer treatment composition and method using natural plant essential oils |
| 10/04/2001 | EP1137425A1 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils |
| 10/04/2001 | EP1137421A1 Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation |
| 10/04/2001 | EP1137419A1 Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid |
| 10/04/2001 | EP1137418A2 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
| 10/04/2001 | EP1137417A1 Use of selected modulators of p2 purinoceptors for the prevention of damage and mortality caused by global cerebral ischemia and ischemia-reperfusion |
| 10/04/2001 | EP1137414A1 Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis |
| 10/04/2001 | EP1137409A2 Compositions and methods for amelioration of human female sexual dysfunction |
| 10/04/2001 | EP1137401A1 Administration of neurotrophic agents to the central nervous system |
| 10/04/2001 | EP1079852B1 Composition based on pentoxifylline and anticytokin |
| 10/04/2001 | EP0675689B1 Medical foods for the nutritional support of child/adult metabolic diseases |
| 10/04/2001 | DE10014588A1 Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone |
| 10/04/2001 | CA2429196A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 10/04/2001 | CA2405502A1 Method of treating hepatitis delta viral infection |
| 10/04/2001 | CA2404756A1 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 10/04/2001 | CA2404712A1 Synergistic methods and compositions for treating cancer comprising antiproliferative cytotoxic and cytostatic agents |
| 10/04/2001 | CA2404574A1 Isolated human g-protein coupled receptors that are members of the aminergic subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 10/04/2001 | CA2404570A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 10/04/2001 | CA2404563A1 Isolated human g-protein coupled receptors of the mas proto-oncogene subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 10/04/2001 | CA2404533A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 10/04/2001 | CA2404532A1 Method of identifying inhibitors of tie-2 |
| 10/04/2001 | CA2404496A1 Calcium binding regulatory subunit |
| 10/04/2001 | CA2404495A1 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 10/04/2001 | CA2404493A1 A method for screening for autoimmune disease by identifying polymorphisms in il-12 p40 |
| 10/04/2001 | CA2404461A1 Human g-protein coupled receptors |
| 10/04/2001 | CA2404432A1 Compositions and methods for identifying and targeting cancer cells |